Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

Frontiers in Oncology

Oncology

Glenn J. Hanna¹  Karthik Ramakrishnan²  Liya Wang²  Daisuke Goto²  Gleicy M. Hair²  Vladimir Turzhitsky²  Christopher M. Black² 

[1] Center for Head & Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, United States;Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ, United States;

关键词: head and neck squamous cell carcinoma;    antineoplastic agents;    immunological;    antibodies;    Kaplan-Meier estimate;    patient outcomes;    real-world observational study;    treatment patterns;   

DOI  :  10.3389/fonc.2023.1240947

 received in 2023-06-17, accepted in 2023-06-30,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Black, Hanna, Wang, Ramakrishnan, Goto, Turzhitsky and Hair